Next-Generation SARS-CoV-2 Vaccine Platform
Legal Citation
Summary of the Inventive Concept
A novel, personalized, and self-amplifying RNA-based vaccine platform for inducing immunity against SARS-CoV-2 and its variants, featuring optimized spike and nucleocapsid proteins, nanoparticle-based adjuvants, and real-time immune response monitoring.
Background and Problem Solved
The original patent disclosed a method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid immunogens delivered by a replication-defective adenovirus. However, this approach has limitations in terms of scalability, personalization, and adaptability to emerging variants. The new inventive concept addresses these limitations by introducing a self-amplifying RNA vaccine platform that can be tailored to individual patients and adapted to new variants.
Detailed Description of the Inventive Concept
The next-generation vaccine platform comprises a self-amplifying RNA vaccine encoding optimized spike and nucleocapsid proteins, which are designed for cell surface expression and endosomal targeting, respectively. The platform also incorporates nanoparticle-based adjuvants to enhance immunogenicity. Additionally, the system features real-time immune response monitoring, enabling personalized adjustments to the vaccine composition. This approach enables rapid adaptation to emerging variants and provides a scalable solution for global vaccine distribution.
Novelty and Inventive Step
The new inventive concept introduces several novel features, including the use of self-amplifying RNA vaccines, optimized spike and nucleocapsid proteins, nanoparticle-based adjuvants, and real-time immune response monitoring. These features provide a significant improvement over the original patent and enable a more effective and adaptable response to the SARS-CoV-2 pandemic.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different RNA vaccine formats, such as mRNA or saRNA, or the incorporation of additional immunogens, such as membrane protein or envelope protein. Variations could also include the use of different adjuvants or delivery methods, such as intramuscular injection or oral administration.
Potential Commercial Applications and Market
The next-generation SARS-CoV-2 vaccine platform has significant commercial potential in the global vaccine market, which is projected to reach $64 billion by 2027. The platform's adaptability to emerging variants and ability to provide personalized immunity make it an attractive solution for governments, healthcare organizations, and pharmaceutical companies seeking to combat the ongoing pandemic.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/215 |
| A | A61 | A61K39/39 |
| C | C12 | C12N15/86 |
| A | A61 | A61K2039/545 |
| A | A61 | A61K2039/55505 |
| A | A61 | A61P31/14 |
| C | C12 | C12N2710/10343 |
| C | C12 | C12N2770/20022 |
| C | C12 | C12N2770/20034 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Vaccine development and immunology, specifically focused on viral vaccines, RNA vaccine technologies, and immunization strategies for respiratory viruses like SARS-CoV-2
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with expertise in molecular biology, virology, immunology, and vaccine design, possessing advanced degrees (PhD or equivalent), familiarity with RNA vaccine platforms, viral protein engineering, and immunization techniques
Obviousness Rationale
A person having ordinary skill in the art would recognize that the PTD represents a predictable extension of the source patent's core vaccine methodology, incorporating known techniques in RNA vaccine design, protein optimization, and personalized immunization strategies. The variations demonstrate incremental improvements using standard techniques in vaccine development, such as self-amplifying RNA, protein targeting sequences, and adaptive immunization approaches. These modifications would be considered routine engineering adaptations within the established vaccine development paradigm.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,620 |
|---|---|
| Title | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| Assignee(s) | ImmunityBio, Inc. |